NOXXON Pharma AG is an independent biopharmaceutical company focusing on the development of innovative pharmaceutical products based on its unique proprietary Spiegelmer® Technology. The company is concentrating its attention on inflammatory diseases and haematological conditions. NOXXON's lead compound, NOX-E36 for treatment of kidney inflammation, is has successfully completed phase I clinical testing. A second Spiegelmer compound, NOX-A12 for use in hematopoietic stem cell transplantation and/or hematological or solid tumors, is in phase I clinical testing.

NOXXON's goal is the in-house development of our own Spiegelmer products through Phase II clinical trials. Complementing its own programs, NOXXON works on multiple drug discovery and development projects with its partners Eli Lilly and F. Hoffmann-La Roche. The pursuit of licensing partnerships and collaborative Research & Development efforts is an integral part of our business strategy and plays an important role in the company's growth and success. This strategy reflects our strengths in drug discovery and  the vast potential of our unique technology platform.